The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor

J. P. Lawrence, J. Ishizuka, B. Haber, C. M. Townsend, J. C. Thompson

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.

Original languageEnglish (US)
Pages (from-to)1131-1135
Number of pages5
Issue number6
StatePublished - 1990

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor'. Together they form a unique fingerprint.

Cite this